AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

15.360

-0.290-1.85%

Volume:1.09M

Turnover:16.81M

Market Cap:5.20B

PE:115.43

High:15.590

Open:15.390

Low:15.260

Close:15.650

52wk High:18.320

52wk Low:8.260

Shares:338.72M

Float Shares:275.41M

Volume Ratio:0.85

T/O Rate:0.40%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.133

EPS(LYR):-0.029

ROE:7.36%

ROA:2.71%

PB:7.65

PE(LYR):-521.81

Loading ...

Overview Company News Filings

Telix study shows Zircaix PET/CT predicts kidney cancer beyond clear-cell RCC

Insider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of Shares

Simply Wall St.

Does New TLX597-Tx Data And Pipeline Progression Change The Bull Case For Telix (ASX:TLX)?

Simply Wall St.

BUZZ-Australia's Telix gains as Europe accepts brain cancer imaging therapy marketing application

BRIEF-Telix Pharmaceuticals Says TLX101-PX (PIXLUMI®) MAA Accepted In Europe

Telix TLX101-Px glioma imaging MAA accepted for EU review

Telix Pharmaceuticals Ltd - Tlx101-Px (Pixlumi®) Maa Accepted in Europe

THOMSON REUTERS

Telix Phase 2 OPTIMAL-PSMA trial shows favorable dosimetry for TLX597-Tx radioligand therapy

Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After New Trial Data Plans And Regeneron Collaboration

Simply Wall St.

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

Telix to host webinar on next-generation PSMA-targeted prostate cancer therapy

ASX Biggest Losers

MT Newswires Live

ASX Growth Leaders With High Insider Ownership April 2026

Simply Wall St.

How Regeneron Tie-Up And Phase 3 Pipeline Advances At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story

Simply Wall St.

Plus Therapeutics starts REYOBIQ manufacturing technology transfer with SpectronRx under MSA

Telix Pharmaceuticals Settles Issue of $600 Million Convertible Notes

MT Newswires Live

BRIEF-Telix Pharmaceuticals Announces Settlement Of $600M Convertible Bonds

Telix Pharmaceuticals Ltd - Telix Announces Settlement of US$600M Convertible Bonds

THOMSON REUTERS

Telix Pharmaceuticals Ltd - New Bonds Expected to Be Listed on Sgx-St on April 23, 2026

THOMSON REUTERS

Telix says ProstACT Global Phase 3 safety data set for ASCO late-breaking oral session

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/TLX.AU/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":15.36,"timestamp":1788156720000,"preClose":15.65,"halted":0,"volume":1092733,"delay":0,"changeRate":-0.018530351437699738,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":0.13306827376468292,"marketStatus":"Not Yet Opened","change":-0.29,"latestTime":"08-31 16:12:00 AEST","open":15.39,"high":15.59,"low":15.26,"amount":16808567,"amplitude":0.021086,"askPrice":15.36,"askSize":33,"bidPrice":15.3,"bidSize":30,"shortable":3,"etf":0,"ttmEps":0.13306827376468292,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":15.65,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":0.847901,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":15.65,"auctionPrice":15.36,"auctionVolume":454441,"auction":3,"marketStatus":"盘后竞价","timestamp":1788156606440}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.71%","roe":"7.36%","lyrEps":-0.029436,"volumeRatio":0.847901,"shares":338721355,"dividePrice":0,"high":15.59,"amplitude":0.021086,"preClose":15.65,"low":15.26,"week52Low":8.26,"pbRate":"7.65","psRate":"4.19","week52High":18.32,"institutionHeld":0,"latestPrice":15.36,"committee":-0.047619,"eps":0.13306827376468292,"divideRate":0,"volume":1092733,"delay":0,"ttmEps":0.13306827376468292,"open":15.39,"prevYearClose":11.2,"prevWeekClose":15.65,"prevMonthClose":14.21,"prevQuarterClose":16.58,"fiveDayClose":16.16,"twentyDayClose":14.28,"sixtyDayClose":13.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787184000000,"name":null,"time":"","dateTimestamp":1787148000000,"actualEps":null},{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633838961","title":"Telix study shows Zircaix PET/CT predicts kidney cancer beyond clear-cell RCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2633838961","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633838961?lang=en_us&edition=fundamental","pubTime":"2026-05-05 05:00","pubTimestamp":1777928422,"startTime":"0","endTime":"0","summary":"Telix published an independent analysis of Phase 3 ZIRCON trial data in European Urology, with results already presented as a new journal publication.Study found TLX250-Px  PET/CT imaging could help identify kidney cancer across multiple renal tumor subtypes, extending potential use beyond clear cell renal cell carcinoma.Findings suggest a positive scan may support clinical decision-making by distinguishing malignant disease from less aggressive tumors, with implications for managing non-clear cell renal cell carcinoma.Telix noted these exploratory results were not part of its Biologics License Application submission, which remains focused on detecting clear cell renal cell carcinoma in primary renal masses.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL4tFmsc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2T93.GBP","LU0314104364.USD","BK7067","SG9999014005.SGD","LU2210149790.SGD","NDAQ","BK4588","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","BK4585","BK4112","IE00BKPKM429.USD","SG9999014021.USD","IE00BN0W2V16.EUR","TLX.AU","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632705906","title":"Insider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2632705906","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632705906?lang=en_us&edition=fundamental","pubTime":"2026-05-03 06:02","pubTimestamp":1777759366,"startTime":"0","endTime":"0","summary":"Those following along with Telix Pharmaceuticals Limited ( ASX:TLX ) will no doubt be intrigued by the recent purchase...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/insider-buying-telix-pharmaceuticals-co-founder-bought-us997","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/insider-buying-telix-pharmaceuticals-co-founder-bought-us997","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX","TLX.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623733","title":"Does New TLX597-Tx Data And Pipeline Progression Change The Bull Case For Telix (ASX:TLX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623733","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632623733?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:45","pubTimestamp":1777668303,"startTime":"0","endTime":"0","summary":"In late April 2026, Telix Pharmaceuticals reported Phase 2 OPTIMAL-PSMA dosimetry data for its second-generation prostate cancer candidate TLX597-Tx, showing low radiation uptake in non-target organs and supporting further evaluation in earlier-stage disease, while also progressing a Regeneron collaboration and a European review of its glioma imaging agent TLX101-Px.\nThese developments highlight how Telix is trying to build an integrated radiopharmaceutical platform, pairing next-generation...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-new-tlx597-tx-data-and-pipeline-progression-change-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-new-tlx597-tx-data-and-pipeline-progression-change-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK7067","TLX","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632968716","title":"BUZZ-Australia's Telix gains as Europe accepts brain cancer imaging therapy marketing application","url":"https://stock-news.laohu8.com/highlight/detail?id=2632968716","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632968716?lang=en_us&edition=fundamental","pubTime":"2026-05-01 09:28","pubTimestamp":1777598939,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix gains as Europe accepts brain cancer imaging therapy marketing application** Shares of Telix Pharmaceuticals TLX.AX rise as much as 3.7% to A$15.55 in early trade, their highest level since April 14** Biopharma major says marketing authorisation application for its TLX101-Px therapy has been validated and accepted for review in Europe** TLX101-Px is an imaging candidate for characterisation of glioma, a form of brain cancer** Says application, which covers commercially significant European markets, has now moved into a 210-day active assessment phase** Stock up 37.4% YTD, including the day's moves  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nL4N41E018:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632957126","title":"BRIEF-Telix Pharmaceuticals Says TLX101-PX (PIXLUMI®) MAA Accepted In Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2632957126","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632957126?lang=en_us&edition=fundamental","pubTime":"2026-05-01 09:15","pubTimestamp":1777598129,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Says TLX101-PX  MAA Accepted In EuropeMay 1  - Telix Pharmaceuticals Ltd TLX.AX:TLX101-PX  MAA ACCEPTED IN EUROPETLX101-TX GRANTED ORPHAN DRUG DESIGNATION IN EUROPE AND U.S.Further company coverage: TLX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nFWN41D1O8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632676886","title":"Telix TLX101-Px glioma imaging MAA accepted for EU review","url":"https://stock-news.laohu8.com/highlight/detail?id=2632676886","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632676886?lang=en_us&edition=fundamental","pubTime":"2026-05-01 06:15","pubTimestamp":1777587355,"startTime":"0","endTime":"0","summary":"Telix European marketing authorization application for TLX101-Px  validated, accepted for review.Review enters 210-day active assessment phase under European regulator process.Positive Day 210 outcome would clear path for national marketing authorizations shortly after.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL24tFDx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4112","SG9999014039.USD","IE00BN0W2V16.EUR","TLX.AU","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD","SG9999014013.SGD","BK7067","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BGHQF748.EUR","NDAQ","BK4585","BK4588","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632662674","title":"Telix Pharmaceuticals Ltd - Tlx101-Px (Pixlumi®) Maa Accepted in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2632662674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632662674?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:43","pubTimestamp":1777585438,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41D1O8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631280524","title":"Telix Phase 2 OPTIMAL-PSMA trial shows favorable dosimetry for TLX597-Tx radioligand therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2631280524","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631280524?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:17","pubTimestamp":1777497427,"startTime":"0","endTime":"0","summary":"Telix presented initial dosimetry results from randomized Phase 2 OPTIMAL-PSMA trial of TLX597-Tx at IPCS 2026, outlining a safety profile that could support more intensive dosing.Data indicated reduced radiation exposure to salivary glands and kidneys, a finding that could lower treatment-limiting side effects and improve tolerability.Telix framed results as supportive of moving TLX597-Tx into earlier-stage metastatic hormone-sensitive prostate cancer, where quality-of-life constraints can limit use of existing radioligand therapies.Company plans to initiate OPTIMAL-E, a Phase 2 study in androgen pathway-sensitive metastatic prostate cancer, to extend evaluation beyond advanced disease.Program sits alongside TLX591-Tx, Telix’s Phase 3 ProstACT Global candidate in mCRPC, positioning portfolio for stage-specific prostate cancer treatment strategies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL6t2JZ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631527403","title":"Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After New Trial Data Plans And Regeneron Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2631527403","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631527403?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:09","pubTimestamp":1777496942,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has drawn fresh attention after announcing plans to showcase OPTIMAL-PSMA 2 data on its TLX597-Tx candidate, alongside upcoming TLX591-Tx trial results and a new collaboration with Regeneron Pharmaceuticals.\nSee our latest analysis for Telix Pharmaceuticals.\nThese clinical updates and the Regeneron partnership arrive during a period of strong share price momentum, with Telix recording a 15.03% 1 month share price return and a 35.38% 3 month share price return,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-new-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-new-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","TLX.AU","BK7067","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631516078","title":"Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516078","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631516078?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:01","pubTimestamp":1777464060,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals got a quiet reception from Wall Street on Wednesday despite a first-quarter earnings beat, as investors remain fixated on the release of key data later this year.The Tarrytown, N.Y.-based drugmaker posted adjusted earnings of $9.47 a share, handily beating the $8.89 Wall Street had anticipated. Revenue ticked higher to $3.61 billion from $3.03 billion last year, surpassing analysts' calls for $3.48 billion.Sales of Dupixent, the blockbuster anti-inflammatory drug co-developed with Sanofi, rose 33% to $4.9 billion in the first quarter. Dupixent recently was approved by both U.S. and European regulators for young children with chronic spontaneous urticaria, and was separately approved by the Food and Drug Administration to treat allergic fungal rhinosinusitis.Other products didn't fare as well. Sales of the standard formulation of Eylea, a prescription ophthalmologic medicine, fell 10% to $941 million. However, sales of higher-dose Eylea HD surged 52% to $468 mi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU2362541513.USD","REGN","BK4139","BK4585","LU0889565916.HKD","LU1974910355.USD","IE00BFXG1179.USD","LU2023250504.SGD","BK4007","LU0823416689.USD","LU0114720955.EUR","LU2237438978.USD","LU2362541273.HKD","TLX.AU","BK7067","LU2362540622.SGD","LU0823434740.USD","LU0823434583.USD","BK4588","LU1917777945.USD","LU0882574055.USD","LU2468319806.SGD","LU2089984988.USD","SNY","LU0053666078.USD","LU0109394709.USD","LU0289739699.SGD","LU2106854487.HKD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630469683","title":"Telix to host webinar on next-generation PSMA-targeted prostate cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2630469683","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630469683?lang=en_us&edition=fundamental","pubTime":"2026-04-28 07:07","pubTimestamp":1777331262,"startTime":"0","endTime":"0","summary":"Telix will host an educational webinar on PSMA-targeted radionuclide therapy on April 30, 2026 at 9:30 a.m. AEST.Session will also run on April 29, 2026 at 7:30 p.m. EDT.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL8LZqpR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630652359","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2630652359","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630652359?lang=en_us&edition=fundamental","pubTime":"2026-04-27 11:59","pubTimestamp":1777262349,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech : -3%, AU$42.79NexGen Energy : -3%, AU$17.26Telix Pharmaceuticals : -2%, AU$14.47Cochlear : -2%, AU$94.76Paladin Energy : -2%, AU$12.28Origin Energy : -2%, AU$12.44EVT : -2%, AU$12.44Tuas : -2%, AU$5.97Ramsay Health Care : -2%, AU$39.15Southern Cross Gold : -2%, AU$11.07","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7509","BK7503","SX2.AU","EVT.AU","TUA.AU","WTC.AU","BK7067","BK7035","BK7016","BK7507","BK7042","COH.AU","BK7113","BK7130","ORG.AU","BK7007","BK7104","RHC.AU","NXG.AU","BK7006","PDN.AU","TLX.AU","BK7083"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630331928","title":"ASX Growth Leaders With High Insider Ownership April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630331928","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630331928?lang=en_us&edition=fundamental","pubTime":"2026-04-27 03:08","pubTimestamp":1777230494,"startTime":"0","endTime":"0","summary":"As the Australian share market shows resilience with a +0.4% advance amidst global uncertainties, particularly contrasting Wall Street's downturn, investors are keenly observing how local factors such as potential interest rate changes influence trading sentiment. In this environment, companies with high insider ownership often attract attention for their perceived alignment of interests between management and shareholders, making them notable candidates for those seeking growth opportunities...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-leaders-with-high-insider-ownership-april-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-leaders-with-high-insider-ownership-april-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","EIQ.AU","TOR.AU","IMA.AU","XJO.AU","BK7095","BK7110","AMI.AU","BK4139","BK7023","FRS.AU","TTT.AU","BK7067","AV1.AU","TLX","BK7096","XAO.AU","BK7506","SPL.AU","BK7016","BK7501","BK7113","REG.AU","AR1.AU","BK7036","MAU.AU","BK7104","SKS.AU","XKO.AU","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629584720","title":"How Regeneron Tie-Up And Phase 3 Pipeline Advances At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2629584720","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629584720?lang=en_us&edition=fundamental","pubTime":"2026-04-24 19:05","pubTimestamp":1777028712,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals recently announced several milestones, including the first patient dosed in the pivotal Phase 3 IPAX BrIGHT trial of TLX101-Tx for recurrent glioblastoma and the upcoming presentation of Phase 3 safety data for its prostate cancer therapy TLX591-Tx at the 2026 ASCO Annual Meeting.\nIn parallel, Regeneron Pharmaceuticals and Telix entered a broad collaboration pairing Regeneron’s antibody portfolio with Telix’s radiopharmaceutical platform, potentially expanding Telix’s...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-regeneron-tie-up-and-phase-3-pipeline-advances-at-telix","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-regeneron-tie-up-and-phase-3-pipeline-advances-at-telix","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4139","TLX","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629183506","title":"Plus Therapeutics starts REYOBIQ manufacturing technology transfer with SpectronRx under MSA","url":"https://stock-news.laohu8.com/highlight/detail?id=2629183506","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629183506?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:33","pubTimestamp":1776943988,"startTime":"0","endTime":"0","summary":"Plus Therapeutics began manufacturing activities with SpectronRx under a previously executed master services agreement to support GMP pivotal-trial readiness for REYOBIQ.SpectronRx will serve as a second GMP manufacturing site alongside Radiomedix, with Rhenium-186 isotope supply sourced through Telix Pharmaceuticals.Technology transfer to SpectronRx covers REYOBIQ manufacturing process, Rhenium-186 processing, analytical methods.SpectronRx facility in Indiana will provide on-demand production for both Rhenium-186 and REYOBIQ in one site to streamline logistics.Plus is targeting completion of manufacturing scale-up for late-stage clinical supply needs in 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL47wJfl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014013.SGD","BK7067","NDAQ","LU0314104364.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2T93.GBP","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2W23.USD","PSTV","TLX.AU","BK4112","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4585","BK4588","BK4139","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629809008","title":"Telix Pharmaceuticals Settles Issue of $600 Million Convertible Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2629809008","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629809008?lang=en_us&edition=fundamental","pubTime":"2026-04-23 10:16","pubTimestamp":1776910582,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said it settled the issue of $600 million in 1.50% convertible notes due 2031, according to a Thursday Australian bourse filing.The convertible notes are expected to be listed on the Official List of the Singapore Exchange Securities Trading on Thursday.In the same filing, the company said that the repurchase of around AU$637 million in principal of the AU$650 million worth of 2.375% convertible bonds due 2029 is \"substantially complete.\"After the repurchase, given that less than 15% in aggregate principal amount of the existing bonds will remain outstanding, Telix said it plans to exercise its right to repurchase and cancel all of the remaining existing bonds at their principal amount.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","BK7067","BK4139","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629507036","title":"BRIEF-Telix Pharmaceuticals Announces Settlement Of $600M Convertible Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2629507036","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629507036?lang=en_us&edition=fundamental","pubTime":"2026-04-23 09:37","pubTimestamp":1776908256,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Announces Settlement Of $600M Convertible BondsApril 23  - Telix Pharmaceuticals Ltd TLX.AX:TELIX ANNOUNCES SETTLEMENT OF US$600M CONVERTIBLE BONDSNEW BONDS EXPECTED TO BE LISTED ON SGX-ST ON APRIL 23, 2026Further company coverage: TLX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nFWN4151CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629207191","title":"Telix Pharmaceuticals Ltd - Telix Announces Settlement of US$600M Convertible Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2629207191","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629207191?lang=en_us&edition=fundamental","pubTime":"2026-04-23 07:42","pubTimestamp":1776901325,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nFWN4151CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629071917","title":"Telix Pharmaceuticals Ltd - New Bonds Expected to Be Listed on Sgx-St on April 23, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629071917","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629071917?lang=en_us&edition=fundamental","pubTime":"2026-04-23 07:42","pubTimestamp":1776901325,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nFWN4151CA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629706821","title":"Telix says ProstACT Global Phase 3 safety data set for ASCO late-breaking oral session","url":"https://stock-news.laohu8.com/highlight/detail?id=2629706821","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629706821?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:49","pubTimestamp":1776804573,"startTime":"0","endTime":"0","summary":"Telix flagged preliminary safety and dosimetry findings from Part 1 of its ProstACT Global Phase 3 study as a late-breaking oral presentation at ASCO 2026.Data will be presented June 1, 2026, covering TLX591-Tx used with standard of care in PSMA-positive metastatic castration-resistant prostate cancer.Part 1 supports trial progression by evaluating tolerability, biodistribution, and radiation dose profile in a lead-in setting.ProstACT Global compares TLX591-Tx combined with standard of care versus standard of care alone, aiming to support broad adoption across major markets.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDLYQBMN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4588","IE00BN0W2W23.USD","LU2095319765.USD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","BK4112","BK4585","LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","BK7067","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":198,"code":"91000000","status":"200"}]}}